Skip to main content

Advertisement

SpringerLink
Log in

Parkinson disease

Another player in gene therapy for Parkinson disease

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Gene therapies have entered clinical trials for several neurological disorders, most notably Parkinson disease. A study in a nonhuman primate model of Parkinson disease has reported motor deficit improvements following the use of a lentiviral vector to restore extracellular dopamine levels. A clinical trial is now underway to evaluate the effectiveness of this approach in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jarraya, B. et al. Dopamine gene therapy for Parkinson's Disease in a nonhuman primate without associated dyskinesia. Science Trans. Med. 1, 1–10 (2009).

    Article  Google Scholar 

  2. Kaplitt, M. G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369, 2097–2105 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Marks, W. J. et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7, 400–408 (2008).

    Article  PubMed  Google Scholar 

  4. Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology doi:10.1212/WNL.0b013e3181c29356.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Muramatsu, S. et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13, 345–354 (2002).

    Article  CAS  PubMed  Google Scholar 

  6. Bankiewicz, K. S. et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp. Neurol. 197, 363–372 (2006).

    Article  CAS  PubMed  Google Scholar 

  7. Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710–719 (2001).

    Article  CAS  PubMed  Google Scholar 

  8. Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54, 403–414 (2003).

    Article  PubMed  Google Scholar 

  9. Ma, Y. et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 52, 628–634 (2002).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, Weill Cornell Medical College, 525 East 68th Street, Box 99, New York, 10065, NY, USA

    Michael G. Kaplitt

Authors
  1. Michael G. Kaplitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

M. G. Kaplitt acts as a consultant for and receives grant support from Neurologix. He also is a stockholder and patent holder with this company.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaplitt, M. Another player in gene therapy for Parkinson disease. Nat Rev Neurol 6, 7–8 (2010). https://doi.org/10.1038/nrneurol.2009.214

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.214

  • Springer Nature Limited

This article is cited by

Search

Navigation